BOSUTINIB MONOHYDRATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for bosutinib monohydrate and what is the scope of freedom to operate?
Bosutinib monohydrate
is the generic ingredient in one branded drug marketed by Pf Prism Cv and is included in two NDAs. There are five patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Bosutinib monohydrate has eighty-one patent family members in thirty countries.
There is one drug master file entry for bosutinib monohydrate. Two suppliers are listed for this compound.
Summary for BOSUTINIB MONOHYDRATE
International Patents: | 81 |
US Patents: | 5 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 2 |
Drug Master File Entries: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 21 |
Clinical Trials: | 1 |
Patent Applications: | 57 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for BOSUTINIB MONOHYDRATE |
DailyMed Link: | BOSUTINIB MONOHYDRATE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for BOSUTINIB MONOHYDRATE
Generic Entry Dates for BOSUTINIB MONOHYDRATE*:
Constraining patent/regulatory exclusivity:
TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML), NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY Dosage:
TABLET;ORAL |
Generic Entry Dates for BOSUTINIB MONOHYDRATE*:
Constraining patent/regulatory exclusivity:
TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML), NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for BOSUTINIB MONOHYDRATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
City of Hope Medical Center | Phase 1 |
National Cancer Institute (NCI) | Phase 1 |
Pharmacology for BOSUTINIB MONOHYDRATE
Drug Class | Kinase Inhibitor |
Mechanism of Action | Bcr-Abl Tyrosine Kinase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for BOSUTINIB MONOHYDRATE
Paragraph IV (Patent) Challenges for BOSUTINIB MONOHYDRATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
BOSULIF | Tablets | bosutinib monohydrate | 400 mg | 203341 | 1 | 2018-10-25 |
BOSULIF | Tablets | bosutinib monohydrate | 100 mg and 500 mg | 203341 | 2 | 2016-09-06 |
US Patents and Regulatory Information for BOSUTINIB MONOHYDRATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pf Prism Cv | BOSULIF | bosutinib monohydrate | CAPSULE;ORAL | 217729-002 | Sep 26, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | CAPSULE;ORAL | 217729-002 | Sep 26, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-003 | Oct 27, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-003 | Oct 27, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-001 | Sep 4, 2012 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BOSUTINIB MONOHYDRATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-003 | Oct 27, 2017 | ⤷ Sign Up | ⤷ Sign Up |
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-001 | Sep 4, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-002 | Sep 4, 2012 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for BOSUTINIB MONOHYDRATE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Cyprus | 1114781 | ⤷ Sign Up | |
Cyprus | 1115251 | ⤷ Sign Up | |
Denmark | 2478905 | ⤷ Sign Up | |
Japan | 2016074700 | 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置 (TREATMENT OF IMATINIB RESISTANT LEUKEMIA USING 4-AMINOQUINOLINE-3-CARBONITRILES) | ⤷ Sign Up |
Mexico | 2009013069 | TRATAMIENTO DE LEUCEMIA RESISTENTE AL IMATINIB. (TREATMENT OF IMATINIB RESISTANT LEUKEMIA.) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for BOSUTINIB MONOHYDRATE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1902029 | C20140016 00110 | Estonia | ⤷ Sign Up | PRODUCT NAME: BOSUTINIIB;REG NO/DATE: K(2013)1968 (LOPLIK) 02.04.2013 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.